Inhibitor Therapeutics, Inc. 10-K Cybersecurity GRC - 2024-03-29

Page last updated on April 11, 2024

Inhibitor Therapeutics, Inc. reported their cybersecurity risk management and governance process in a yearly 10-K filed on 2024-03-29 16:05:43 EDT.

Filings

10-K filed on 2024-03-29

Inhibitor Therapeutics, Inc. filed an 10-K at 2024-03-29 16:05:43 EDT
Accession Number: 0001493152-24-011973

Note: filing items unformatted. Drop us a note with the above URL to help us prioritize formatting it!

Item 1C. Cybersecurity.

Item 1C. Cybersecurity We recognize the importance of assessing, identifying, and managing material risks associated with cybersecurity threats, as such term is defined in Item 106(a) of Regulation S-K. These risks include, among other things: operational risks, intellectual property theft, fraud, extortion, harm to employees or customers and violation of data privacy or security laws. Identifying and assessing cybersecurity risk is integrated into our overall risk management systems and processes. Cybersecurity risks related to our business, technical operations, privacy and compliance issues are identified and addressed through a multi-faceted approach including third party assessments, internal IT Audit, IT security, governance, risk and compliance reviews. To defend, detect and respond to cybersecurity incidents, we, among other things: conduct proactive privacy and cybersecurity reviews of systems and applications, audit applicable data policies, perform penetration testing using external third-party tools and techniques to test security controls, conduct employee training, monitor emerging laws and regulations related to data protection and information security and implement appropriate changes. Our risk management program also assesses third party risks, and we perform third-party risk management to identify and mitigate risks from third parties such as vendors, suppliers, and other business partners associated with our use of third-party service providers. Cybersecurity risks are evaluated when determining the selection and oversight of applicable third-party service providers and potential fourth-party risks when handling and/or processing our employee, business or vendor data. In addition to new vendor onboarding, we would perform risk management during potential third-party cybersecurity compromise incidents, should they occur, to identify and mitigate risks to us from third-party incidents. In addition, we maintain cybersecurity insurance coverage (first and third-party) with an insurance carrier that is a leader in the cybersecurity insurance industry.


Company Information

NameInhibitor Therapeutics, Inc.
CIK0001042418
SIC DescriptionPharmaceutical Preparations
TickerINTI - OTC
Website
CategoryNon-accelerated filer
Smaller reporting company
Fiscal Year EndDecember 30